The first patient has been dosed in a Phase 1 trial testing ACU193, an antibody designed by Acumen Pharmaceuticals to target toxic forms of amyloid beta — called amyloid-beta oligomers — as a potential therapy for early Alzheimer’s disease. The INTERCEPT-AD Phase 1 trial (NCT04931459) is expecting to enroll approximately 62 patients, ages 55-85, with mild cognitive impairment or mild dementia due to Alzheimer’s disease, across six clinical sites in Arizona, Florida, Georgia, and Ohio. Recruitment…
You must be logged in to read/download the full post.
The post Dosing Begins in ACU193 Trial, Targeting Toxic Amyloid Beta appeared first on BioNewsFeeds.